Qure.ai introduces FDA-cleared AI solution for advanced lung nodule quantification on CT scans at AABIP (American Association for Bronchology and Interventional Pulmonology) 2024

Qure.ai, a leader in medical imaging AI, has secured a significant 510(k) FDA clearance for its AI-powered chest CT solution, qCT LN Quant. This tool is designed to assist radiologists and pulmonologists in analyzing lung nodules on non-contrast chest CT scans and tracking their volumetric growth for progression monitoring.

qCT LN Quant is part of Qure.ai’s comprehensive Lung Cancer care continuum in the U.S., which includes AI solutions like ‘qXR LN’ for early lung nodule detection on chest X-rays and ‘qTrack,’ a multi-modality lung nodule management platform integrated with Electronic Medical Records (EMRs). The system allows for detailed analysis across multiple thoracic studies, offering 2D and 3D reconstructions, Brock malignancy risk scores, and management suggestions based on Fleischner Society guidelines.

Unveiled at the AABIP conference in North Carolina, this FDA clearance represents a major step in enhancing lung cancer care in the U.S., particularly in areas with low CT screening rates.